Trial Condition(s):

Hypertension, Pulmonary

non-interventional, postauthorization safety study of Ventavis for Pulmonary Arterial Hypertension (PAH)

Bayer Identifier:

17941

ClinicalTrials.gov Identifier:

NCT02825160

EudraCT Number:

Not Available

Recruiting

Trial Purpose

This study is collecting post-marketing information on
the safety and effectiveness of Ventavis under the
routine clinical practice for patients with PAH

Inclusion Criteria
- Patients diagnosed with PAH
- Patients for whom the decision to initiate treatment with Ventavis was made as per investigator’s routine treatment practice.
Exclusion Criteria
- N/A

Trial Summary

Enrollment Goal
270
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Ventavis (Iloprost, BAYQ6256)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

many locations

many locations, Japan

Status
Recruiting
 

Trial Design